Rothstein, Betsy
June 2007
Hill;6/13/2007, Vol. 14 Issue 70, p34
An interview with top model CariDee English is presented. English goes with people's views concerning political party preference in the U.S. She had psoriasis for 15 years and the first time she had it is when she was five years old. It covered 70 percent of her body, but had cleared it up when she took a medication. She reiterated that it is a lot easier for her to discuss this private problem publicly.


Related Articles

  • I WEAR LONG-SLEEVED SHIRTS all year. Summerfield, Julie // Woman's Day (Australia Edition);9/23/2002, p38 

    Presents an article on a mother who had a psoriasis. Symptoms of the disease; Treatments.

  • New Insights on Psoriasis. Norsted, Hanna // Acta Dermato-Venereologica;May2014, Vol. 94 Issue 3, following p264 

    An introduction to the journal is presented in which the author mentions two articles published within the issue, namely one about elderly psoriasis patients and another on psoriatic patients' illness perception and subjective health.

  • It's time to reclaim patients with severe psoriasis. Wilson, Fred // Dermatology Times;Sep2004 Supplement, Vol. 25, pS8 

    Discusses treatment issues faced by psoriasis patients in the U.S. Frustrations experienced by both patients and physicians in the treatment process; Statement of dermatologist, Gerald G. Krueger, on the fact that many severely psoriatic patients are not being aggressively treated; Issues that...

  • PostÄ™powanie z chorymi na Å‚uszczycÄ™: ocena postaw i zachowaÅ„ lekarzy oddziałów dermatologicznych w codziennej praktyce lekarskiej. Reich, Adam; Szepietowski, Jacek // Clinical Dermatology / Dermatologia Kliniczna;2011, Vol. 13 Issue 2, p57 

    Introduction: Psoriasis is not only connected with the presence of skin lesions or joint problems, but may increase the risk of diabetes, disease of circulation or obesity. More efficacious and safer systemic therapies improve treatment results of psoriasis, and possibly also reduce the risk of...

  • Alefacept improves quality of life for psoriasis sufferers. Guttman, Cheryl // Dermatology Times;Dec2000, Vol. 21 Issue 12, p35 

    Reports on the efficacy of alefacept in improving the quality of life of psoriatic patients. Results of clinical trial using recombinantly engineered fusion protein; Dosage.

  • Psychosocial component is critical to comprehensive psoriasis approach. Nataloni, Rochelle // Dermatology Times;Sep2005 Supplement 4, Vol. 25, pS25 

    Focuses on the role of psychosocial component to comprehensive psoriasis approach. Assessment of the extent of the psoriasis; Evaluation of the patient's psychosocial needs; Relationship between the extent of tumor lymphangiogenesis and both lymph mode.

  • Pharmacological Undertreatment of Coronary Risk Factors in Patients with Psoriasis: Observational Study of the Danish Nationwide Registries. Ahlehoff, Ole; Skov, Lone; Gislason, Gunnar; Lindhardsen, Jesper; Kristensen, S�ren Lund; Iversen, Lars; Lasthein, Stine; Gniadecki, Robert; Dam, Tomas Norman; Torp-Pedersen, Christian; Hansen, Peter Riis // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: Patients with psoriasis have increased prevalence of coronary risk factors and limited recent results have suggested that these risk factors are undertreated in patients with psoriasis. This may contribute to the increased risk of cardiovascular diseases observed in patients with...

  • Serum Copper, Zinc and Oxidative Stress in Patients with Psoriasis. Alwasiti, Estabraq A. R. K.; Al-Rubayee, Wasan T.; Al-Tammimy, Sami M. // Iraqi Journal of Medical Sciences;2011, Vol. 9 Issue 2, p137 

    Background Psoriasis is a chronic inflammatory skin disease characterized by well-demarcated erythema and scaly plaques. The pathogenesis of psoriasis still remains unclear. An increased reactive oxygen species (ROS) and insufficient antioxidant activity associated with the pathogenesis of...

  • Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept. Kramer, Jesse M.; Turner, James E. // American Journal of Clinical Dermatology;2009, Vol. 10 Issue 2, p134 

    Efalizumab is a recombinant humanized monoclonal antibody approved for the treatment of adult patients with modcrate-to-severe chronic plaque psoriasis. We present six cases of favorable response to efaiizumab therapy in patients with psoriasis who demonstrated inadequate response or who were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics